Alkermes (ALKS) Projected to Post Quarterly Earnings on Thursday

Alkermes (NASDAQ:ALKS) is projected to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Alkermes to post earnings of $0.80 per share and revenue of $379.74 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. On average, analysts expect Alkermes to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Up 4.8 %

NASDAQ ALKS opened at $33.50 on Thursday. Alkermes has a 52 week low of $22.90 and a 52 week high of $33.73. The firm has a market capitalization of $5.42 billion, a price-to-earnings ratio of 17.18, a PEG ratio of 1.83 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The company has a fifty day moving average of $30.16 and a two-hundred day moving average of $28.65.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ALKS shares. HC Wainwright reaffirmed a “neutral” rating and set a $37.00 target price on shares of Alkermes in a research report on Friday, October 25th. Deutsche Bank Aktiengesellschaft started coverage on Alkermes in a research note on Tuesday. They set a “buy” rating and a $40.00 target price on the stock. Piper Sandler restated an “overweight” rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a research note on Friday, October 25th. The Goldman Sachs Group lowered their target price on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, Mizuho upped their price target on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and an average target price of $36.33.

Insider Transactions at Alkermes

In other news, Director Cato T. Laurencin sold 2,691 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now owns 23,013 shares of the company’s stock, valued at $732,964.05. This represents a 10.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Christian Todd Nichols sold 5,208 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the transaction, the senior vice president now owns 60,703 shares of the company’s stock, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 179,189 shares of company stock worth $5,723,518 in the last ninety days. Insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.